Lan Ying Lin

US Patent:

7534764, May 19, 2009

Filed:

Jun 28, 2006

Appl. No.:

11/427095

Inventors:

Tomas Ganz - Los Angeles CA, US
Lan Lin - Los Angeles CA, US
Yigal P. Goldberg - Vancouver, CA

Assignee:

The Regents of the University of California - Oakland CA
Xenon Pharmaceuticals, Inc. - Burnaby, British Columbia

International Classification:

A61K 38/00

US Classification:

514 12

Abstract:

Disclosed herein are hemojuvelin-specific siRNAs that vary hemojuvelin mRNA concentration. Also disclosed herein, GPI-hemojuvelin positively regulated hepcidin mRNA expression, independently of the IL-6 pathway, whereas soluble hemojuvelin (s-hemojuvelin) suppressed hepcidin mRNA expression in primary human hepatocytes in a log-linear dosedependent manner. Disclosed are compositions and methods for modulating diseases of iron metabolism and hepcidin expression or hepcidin levels.

US Patent:

20090233859, Sep 17, 2009

Filed:

Mar 4, 2009

Appl. No.:

12/397589

Inventors:

Tomas Ganz - Los Angeles CA, US
Lan Lin - Iowa City IA, US
Yigal P. Goldberg - Vancouver, CA

International Classification:

A61K 38/16
C12N 5/00
C12N 15/00
G01N 33/68
A61K 38/10
A61K 38/08
C07K 14/00
C07K 7/00

US Classification:

514 12, 435325, 4353201, 436 86, 514 13, 514 14, 514 15, 514 16, 514 17, 530324, 530325, 530326, 530327, 530328, 530329, 530350

Abstract:

Disclosed herein are hemojuvelin-specific siRNAs that vary hemojuvelin mRNA concentration. Also disclosed herein, GPI-hemojuvelin positively regulated hepcidin mRNA expression, independently of the IL-6 pathway, whereas soluble hemojuvelin (s-hemojuvelin) suppressed hepcidin mRNA expression in primary human hepatocytes in a log-linear dose dependent manner. Disclosed are compositions and methods for modulating diseases of iron metabolism and hepcidin expression or hepcidin levels.